Abstract
For many years the neuromodulator adenosine has been recognized as an endogenous anticonvulsant molecule and termed a “retaliatory metabolite.” As the core molecule of ATP, adenosine forms a unique link between cell energy and neuronal excitability. In parallel, a ketogenic (high-fat, low-carbohydrate) diet is a metabolic therapy that influences neuronal activity significantly, and ketogenic diets have been used successfully to treat medically-refractory epilepsy, particularly in children, for decades. To date the key neural mechanisms underlying the success of dietary therapy are unclear, hindering development of analogous pharmacological solutions. Similarly, adenosine receptor – based therapies for epilepsy and myriad other disorders remain elusive. In this review we explore the physiological regulation of adenosine as an anticonvulsant strategy and suggest a critical role for adenosine in the success of ketogenic diet therapy for epilepsy. While the current focus is on the regulation of adenosine, ketogenic metabolism and epilepsy, the therapeutic implications extend to acute and chronic neurological disorders as diverse as brain injury, inflammatory and neuropathic pain, autism and hyperdopaminergic disorders. Emerging evidence for broad clinical relevance of the metabolic regulation of adenosine will be discussed.
Keywords: Metabolism, neuroprotection, neurodegeneration, sleep, pain, autism, addiction, dopamine
Current Neuropharmacology
Title: Adenosine, Ketogenic Diet and Epilepsy: The Emerging Therapeutic Relationship Between Metabolism and Brain Activity
Volume: 7 Issue: 3
Author(s): S. A. Masino, M. Kawamura Jr., C. A. Wasser, L. T. Pomeroy and D. N. Ruskin
Affiliation:
Keywords: Metabolism, neuroprotection, neurodegeneration, sleep, pain, autism, addiction, dopamine
Abstract: For many years the neuromodulator adenosine has been recognized as an endogenous anticonvulsant molecule and termed a “retaliatory metabolite.” As the core molecule of ATP, adenosine forms a unique link between cell energy and neuronal excitability. In parallel, a ketogenic (high-fat, low-carbohydrate) diet is a metabolic therapy that influences neuronal activity significantly, and ketogenic diets have been used successfully to treat medically-refractory epilepsy, particularly in children, for decades. To date the key neural mechanisms underlying the success of dietary therapy are unclear, hindering development of analogous pharmacological solutions. Similarly, adenosine receptor – based therapies for epilepsy and myriad other disorders remain elusive. In this review we explore the physiological regulation of adenosine as an anticonvulsant strategy and suggest a critical role for adenosine in the success of ketogenic diet therapy for epilepsy. While the current focus is on the regulation of adenosine, ketogenic metabolism and epilepsy, the therapeutic implications extend to acute and chronic neurological disorders as diverse as brain injury, inflammatory and neuropathic pain, autism and hyperdopaminergic disorders. Emerging evidence for broad clinical relevance of the metabolic regulation of adenosine will be discussed.
Export Options
About this article
Cite this article as:
Masino A. S., Kawamura Jr. M., Wasser A. C., Pomeroy T. L. and Ruskin N. D., Adenosine, Ketogenic Diet and Epilepsy: The Emerging Therapeutic Relationship Between Metabolism and Brain Activity, Current Neuropharmacology 2009; 7(3) . https://dx.doi.org/10.2174/157015909789152164
DOI https://dx.doi.org/10.2174/157015909789152164 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Editorial [Hot Topic: Nitric Oxide: Implications for the Etiology & Treatment of Central Nervous System Disorders (Guest Editor: Giuseppe Di Giovanni)]
CNS & Neurological Disorders - Drug Targets Nanotechnology and Drug Delivery: Getting There is Only Half of the Challenge! (Commentary)
CNS & Neurological Disorders - Drug Targets Evolving Mechanistic Concepts of Epileptiform Synchronization and their Relevance in Curing Focal Epileptic Disorders
Current Neuropharmacology Conotoxins and Structural Biology: A Prospective Paradigm for Drug Discovery
Current Protein & Peptide Science Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry Adult Neurogenesis in Epileptogenesis: An Update for Preclinical Finding and Potential Clinical Translation
Current Neuropharmacology (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) The Role of MDR1 Genetic Polymorphisms in Interindividual Variability in P-glycoprotein Expression and Function
Current Drug Metabolism Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Neuronal High-Affinity Sodium-Dependent Glutamate Transporters (EAATs): Targets for the Development of Novel Therapeutics Against Neurodegenerative Diseases
Current Pharmaceutical Design Effect of Hemodialysis on Pharmacokinetics of Ezogabine/Retigabine and its N-Acetyl Metabolite in Patients with End Stage Renal Disease
Current Clinical Pharmacology Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review
Current Molecular Pharmacology Perspective on mTOR-dependent Protection in Status Epilepticus
Current Neuropharmacology Metabotropic Glutamate Receptors: A Review on Prospectives and Therapeutic Aspects
Mini-Reviews in Medicinal Chemistry Types of Voltage-Gated Calcium Channels: Molecular and Electrophysiological Views
Current Hypertension Reviews The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Current Drug Targets Adult Stem Cell Application in Spinal Cord Injury
Current Drug Targets Effect of Levetiracetam on Cognitive Function and Clonic Seizure Frequency in Children with Epilepsy
Current Molecular Medicine Conantokins: Peptide Antagonists of NMDA Receptors
Current Medicinal Chemistry Design, Synthesis and Anticonvulsant Activity Evaluation of 7-Substituted –[1,2,4]-Triazolo[4,3-f]Pyrimidine Derivatives
Medicinal Chemistry Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery